Clinical effect of Dienogest in the treatment of recurrent ovarian endometriosis
ZHU Yi-rong1 FANG Shu-fen1 PENG Shu-hua2
1.Department of Gynecology, Jiangxi Maternal and Child Health Hospital, Jiangxi Province, Nanchang 330006, China;
2.Department of Gynecology,Xinjian District Maternal and Child Health Hospital,Jiangxi Province,Nanchang 330006,China
Abstract：Objective To explore the clinical efficacy of Dienogest in the treatment of recurrent ovarian endometriosis(OEM).Methods A total of 40 patients with recurrent OEM admitted to Jiangxi Maternity and Child Health Hospital from September 2019 to March 2020 were selected as the research objects and divided into the control group and the observation group by random number table method, with 20 cases in each group.Patients in the control group were treated with Drospirenone Ethinyl Estradiol Tablets, and in the observation group, patients were treated with Dienogest.The menstruation, endometriotic cyst volume, dysmenorrhea, chronic pelvic pain or dyspareunia visual analogue scale(VAS) score, serum carbohydrate antigen 125 (CA125), blood lipid levels and the incidence of adverse reactions were compared between the two groups before treatment and 3 and 6 months after treatment.Results There were no statistically significant differences in the rate of normal menstrual frequency and normal menstrual period between the two groups after treatment (P＞0.05).There were no statistically significant differences in volume of cysts, VAS score of dysmenorrhea, VAS score of pelvic pain or dyspareunia, serum CA125, triglyceride and total cholesterol between the two groups before treatment (P＞0.05).After 6 months of treatment, the volume of cysts in the observation group was lower than that in the control group, VAS score of dysmenorrhea, VAS score of pelvic pain or dyspareunia and serum CA125 in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05).There were no statistically significant differences in triglyceride, total cholesterol and clinical adverse reactions between the two groups after six months of treatment (P＞0.05).Conclusion Dienogest can significantly relieve pain, reduce the volume of cysts and serum CA125 in OEM patients, and the clinical effect is good.
京公网安备 11010502046607号